Mesuximide

From Wikipedia, the free encyclopedia

Mesuximide

Systematic (IUPAC) name
(RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a682028
Pregnancy cat.	C (US)
Legal status	℞-only (US)
Routes	Oral
Pharmacokinetic data
Metabolism	Hepatic (demethylation and glucuronidation)
Half-life	1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite)
Excretion	Renal
Identifiers
CAS number	77-41-8^Y
ATC code	N03AD03
PubChem	CID 6476
DrugBank	DB05246
ChemSpider	6231^Y
UNII	0G76K8X6C0^Y
KEGG	D00404^Y
ChEMBL	CHEMBL697^Y
Chemical data
Formula	C₁₂H₁₃N O₂
Mol. mass	203.237 g/mol
SMILES O=C2N(C(=O)CC2(c1ccccc1)C)C
InChI InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3^Y Key:AJXPJJZHWIXJCJ-UHFFFAOYSA-N^Y
N (what is this?) (verify)

Mesuximide (or methsuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)^[1] and Celontin (United States).^[2] The therapeutic efficacy of methsuximide is largely due to its pharmacologically active metabolite, N-desmethylmethsuximide, which has a longer half-life and attains much higher plasma levels than its parent.^[3]

References

↑ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Retrieved August 21, 2006.
↑ Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved June 10, 2008.
↑ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.

Anticonvulsants (N03)

GABA_A receptor agonist

Barbiturates	Barbexaclone Metharbital Methylphenobarbital Pentobarbital Phenobarbital^# Primidone

Benzodiazepines	Clobazam Clonazepam Clorazepate Diazepam^# Flutoprazepam Lorazepam Midazolam Nimetazepam Nitrazepam Temazepam

Other GABA agents

Aromatic allylic alcohols	Stiripentol

Carbonic anhydrase inhibitor

Sulfa drugs	Acetazolamide Ethoxzolamide Sultiame Zonisamide

Channel blockers

Primarily sodium

Hydantoins	Ethotoin Fosphenytoin Mephenytoin Phenytoin^#

Carboxamides	Carbamazepine^# Eslicarbazepine acetate Oxcarbazepine Oxitriptyline Rufinamide

Primarily calcium

Succinimides	Ethosuximide^# Mesuximide Phensuximide

AMPA receptor

Perampanel

Unknown/ungrouped

Phenyltriazine (Lamotrigine), Oxazolidinediones (Ethadione
Paramethadione
Trimethadione), Ureas (Phenacemide
Pheneturide), Monosaccharide (Topiramate)

Channel openers

Potassium	Retigabine

Indirect GABA agents

Carboxylic acids/ Fatty acid derivatives	GABA transaminase inhibitor: Valproic acid^# (Sodium valproate & Valproate semisodium) Valpromide Valnoctamide Valproate pivoxil GABA reuptake inhibitor: Tiagabine

GABA analogs	Gabapentin Pregabalin Progabide Tolgabide Vigabatrin

Unknown/multiple/
unsorted

Carbamates/sulfamates	Carisbamate^† Emylcamate Felbamate JNJ-26990990^§ Meprobamate Topiramate

Pyrrolidines	Brivaracetam Levetiracetam Nefiracetam Seletracetam

Propionates	Beclamide Lacosamide

Aldehydes	Paraldehyde

Bromides	Potassium bromide Sodium bromide

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

M: CNS

anat (n/s/m/p/4/e/b/d/c/a/f/l/g)/phys/devp

noco (m/d/e/h/v/s)/cong/tumr, sysi/epon, injr

proc, drug (N1A/2AB/C/3/4/7A/B/C/D)

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.